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Genome-wide association studies (GWAS) have been extremely
successful at identifying replicable associations between
common genetic variants and type 2 diabetes risk. The
latest studies, including 35,000 European (1), 7,000 East
Asian (2), 5,500 South Asian (3), and most recently 3,800
Latin American (4) and 6,000 Japanese (5) type 2 di-
abetes cases, bring the total number of associated var-
iants to more than 70. There is strong evidence that many
of the associated genetic variants lie in or close to genes
important in type 2 diabetes etiology (e.g., the regions of
the genome identiﬁed by GWAS are enriched for mono-
genic diabetes genes, such as HNF1A, HNF1B, and PPARG,
and small noncoding regions of the genome [enhancers]
critical for islet-speciﬁc gene expression [6]). Nevertheless,
the ﬁeld has not moved from genetic associations to im-
proved understanding of biology as quickly or as often as
hoped.
In this issue, Dimas et al. (7) present data that move
the ﬁeld a step closer to mechanisms. They tested the
hypothesis that a systematic analysis of insulin secretion
and insulin resistance measures in nondiabetic individuals
would improve the understanding of the intermediate
mechanisms by which genetic variants predispose to
type 2 diabetes. They performed the most extensive anal-
ysis yet to group variants into categories based on their
likely intermediate mechanism. The authors combined
data from thousands of individuals with fasting-, oral-,
and intravenous-based measures of insulin secretion and
resistance. This approach has been used before for
a smaller number of loci and individuals (8), but here
the authors added a statistical clustering approach to pro-
vide the most robust categorization of the type 2 diabetes
variants. This clustering analysis successfully binned 16
type 2 diabetes risk variants into four broad groups. Four
variants ﬁtted a clear insulin resistance pattern, two re-
duced insulin secretion with fasting hyperglycemia, nine
reduced insulin secretion with normal fasting glycemia,
and one altered insulin processing. A further 20 variants
did not ﬁt a clear physiological category, probably because
of their relatively weaker effects on type 2 diabetes risk.
These ﬁndings move the ﬁeld forward by providing func-
tional biologists with more information about where to
start their experiments.
It could be argued that there are few surprises among
the ﬁndings. For example, the variants categorized as
insulin resistance, those near PPARG, IRS1, GCKR, and
KLF11, either lie near genes with clear roles in insulin
resistance (PPARG, IRS1) or are associated with insulin
resistance–related measures (GCKR [9] and KLF11 [10]).
Likewise, studies have established that diabetes risk
alleles in or near TCF7L2 and SLC30A8 are associated
with reduced insulin secretory capacity in response to
a glucose challenge (8). Nevertheless, the data provide
the strongest evidence yet that those genetic variants in
or near (but not necessarily functioning through) the
PROX1, TMEM, CDKAL1, CDKN2A/B, THADA, HHEX/IDE,
and ADCY5 genes operate primarily through an insulin se-
cretory defect. Dimas et al. also highlight the intriguing
pattern of associations observed with the variant near
ARAP1. Previously noted in a genome-wide study of pro-
insulin levels (11), Dimas et al. categorize this variant as
“insulin processing.” Most type 2 diabetes risk alleles are
associated with raised proinsulin levels, and this is in keep-
ing with the epidemiologic associations (12). In contrast,
the type 2 diabetes risk allele in the ARAP1 locus is associ-
ated with reduced proinsulin levels relative to insulin levels
in the fasting state. The underlying explanation of this
paradoxical ﬁnding is still not known.
The study reemphasizes some old questions and raises
some new questions. Notably, why is it so difﬁcult to
assign an intermediate physiological mechanism to alleles
clearly associated with type 2 diabetes? Despite using up
to 58,000 individuals with fasting measures, 11,000
with oral glucose tolerance tests (OGTTs), and 4,600
with intravenous-based measures including 2,600 with
euglycemic-hyperinsulinemic clamps, Dimas et al. were only
able to group 16 of the 37 strongest type 2 diabetes risk
variants into recognizable categories. Intuitively, a genetic
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risk variant should be associated with the trait that leads
to type 2 diabetes more strongly than diabetes, but this
rarely seems to be the case. Sample size is unlikely to be to
blame—most of the diabetes risk alleles studied were dis-
covered using less than 12,000 cases. One of the most
likely explanations is measurement error. Insulin and, to
a lesser extent, glucose vary within individuals much more
than type 2 diabetes status. Imprecision in measuring
intermediate physiology will reduce statistical power to
detect effects (13), and it is noticeable that 12 of the 16
classiﬁable variants are among the 22 with the strongest
odds ratios for type 2 diabetes. It may be that studies of
12,000 individuals at the ;5% extreme end of the pop-
ulation with the poorest b-cell function and highest in-
sulin resistance (those with diabetes) may be much more
powerful than studies of 12,000 individuals from the
remaining 95% of the distribution.
The explanation of the unclassiﬁed associations may
not be just lack of statistical power. It is also an intriguing
possibility that some variants may not play a role in altering
physiology in normal individuals (at least as assessed by the
submaximal tests performed in these studies), but may be
important in inﬂuencing initial b-cell mass or the rate of
deterioration of b-cell function once diabetes develops.
These possible alternatives may explain why some of the
variants lying close to the known monogenic b-cell genes,
including HNF1A, HNF1B, WFS1, and KCNJ11, were not
grouped into clear physiological categories.
Also worth highlighting are the common genetic
variants noticeable by their absence. Variants in or near
the G6PC2 and MADD (11) genes are among those with
the strongest effects on fasting glycemia and proinsulin
levels, respectively, and yet are not associated (even nom-
inally) with type 2 diabetes. Hence, these variants were
not included in Dimas et al., but further study of these
variants and genes could improve knowledge of b-cell
function. Since the GWAS ﬁnding, the G6PC2 gene (also
called islet-speciﬁc glucose-6-phosphatase–related protein
[IGRP]) has been the subject of renewed interest (14).
These large studies of subtle physiological effects also
allow examination of the rather crude tools available to
examine intermediate traits in large numbers of individ-
uals. It is clear that in normoglycemic individuals the vast
majority of variation in derived homeostasis model
assessment of b-cell function is explained by fasting glu-
cose, and this model adds little. Interestingly, there is not
a clear increase in precision when intravenous glucose
tolerance tests are used rather than OGTT-derived indi-
ces. It would be interesting to examine if the more so-
phisticated modeling of OGTT data using deconvolution
of C-peptide could give new insights (15).
Perhaps the most important general message emerging
from Dimas et al. (7) is that the type 2 diabetes GWAS
ﬁeld needs scientists from other areas—those with exper-
tise in physiology, cell biology, and functional biology—to
carefully inspect the 70 loci, the associated phenotypes,
and the nearby genes. By way of example, follow-up of the
variants and genes in the loci labeled as PROX1, TMEM,
CDKAL1, CDKN2A/B, THADA, HHEX/IDE, and ADCY5
should target insulin secretion mechanisms.
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